Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib

Genes to Cells

Volumn 17, Issue 7, 2012, Pages 548-558

  Uyama, Maki ^a   Sato, Mari M ^a   Kawanami, Masamitsu ^a   Tamura, Masato ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; BORTEZOMIB; LUCIFERASE; OSTEOCALCIN; SMAD1 PROTEIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION;

ANIMALS; BETA CATENIN; BORONIC ACIDS; CELL DIFFERENTIATION; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MICE; MICRORNAS; MUSCLE FIBERS, SKELETAL; OSTEOBLASTS; OSTEOCALCIN; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SMAD1 PROTEIN; SMAD4 PROTEIN; TRANSCRIPTIONAL ACTIVATION;

EUKARYOTA;

EID: 84862753576     PISSN: 13569597     EISSN: 13652443     Source Type: Journal    
DOI: 10.1111/j.1365-2443.2012.01611.x     Document Type: Article

References (39)

1. de Bettignies, G. & Coux, O. (2010) Proteasome inhibitors: dozens of molecules and still counting. Biochimie 92, 1530-1545.
2. Borissenko, L. & Groll, M. (2007) 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev. 107, 687-717.
3. Chen, B., Dodge, M.E., Tang, W., Lu, J., Ma, Z., Fan, C.W., Wei, S., Hao, W., Kilgore, J., Williams, N.S., Roth, M.G., Amatruda, J.F., Chen, C. & Lum, L. (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5, 100-107.
4. Ciechanover, A. (1998) The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17, 7151-7160.
5. Dahlmann, B. (2007) Role of proteasomes in disease. BMC Biochem. 8(Suppl. 1), S3.
6. Dick, L.R. & Fleming, P.E. (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 15, 243-249.
7. Ducy, P. & Karsenty, G. (1995) Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol. Cell. Biol. 15, 1858-1869.
8. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A.L. & Karsenty, G. (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89, 747-754.
9. Garrett, I.R., Chen, D., Gutierrez, G., Zhao, M., Escobedo, A., Rossini, G., Harris, S.E., Gallwitz, W., Kim, K.B., Hu, S., Crews, C.M. & Mundy, G.R. (2003) Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest. 111, 1771-1782.
10. Giuliani, N., Colla, S., Morandi, F., Lazzaretti, M., Sala, R., Bonomini, S., Grano, M., Colucci, S., Svaldi, M. & Rizzoli, V. (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106, 2472-2483.
11. Giuliani, N., Morandi, F., Tagliaferri, S., Lazzaretti, M., Bonomini, S., Crugnola, M., Mancini, C., Martella, E., Ferrari, L., Tabilio, A. & Rizzoli, V. (2007) The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110, 334-338.
12. Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C.O., Fleissner, C., Hecht, M. & Sezer, O. (2006) Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur. J. Haematol. 77, 233-238.
13. Jones, D.C., Wein, M.N., Oukka, M., Hofstaetter, J.G., Glimcher, M.J. & Glimcher, L.H. (2006) Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3. Science 312, 1223-1227.
14. Katagiri, T., Imada, M., Yanai, T., Suda, T., Takahashi, N. & Kamijo, R. (2002) Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells 7, 949-960.
15. Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T., Rosen, V., Wozney, J., Fujisawa-Sehara, A. & Suda, T. (1994) Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127, 1755-1766.
16. Lassot, I., Ségéral, E., Berlioz-Torrent, C., Durand, H., Groussin, L., Hai, T., Benarous, R. & Margottin-Goguet, F. (2001) ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(betaTrCP) ubiquitin ligase. Mol. Cell. Biol. 21, 2192-2202.
17. MacDonald, B., Tamai, K. & He, X. (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9-26.
18. Miyazono, K. & Miyazawa, K. (2002) Id: a target of BMP signaling. Sci. STKE 2002, PE40.
19. Mukherjee, S., Raje, N., Schoonmaker, J.A. et al. (2008) Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J. Clin. Invest. 118, 491-504.
20. Nakashima, A., Katagiri, T. & Tamura, M. (2005) Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J. Biol. Chem. 280, 37660-37668.
21. Obama, H. & Ozawa, M. (1997) Identification of the domain of alpha-catenin involved in its association with beta-catenin and plakoglobin (gamma-catenin). J. Biol. Chem. 272, 11017-11020.
22. Oerlemans, R., Franke, N.E., Assaraf, Y.G., et al. (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112, 2489-2499.
23. Oyajobi, B.O., Garrett, I.R., Gupta, A., Flores, A., Esparza, J., Muñoz, S., Zhao, M. & Mundy, G.R. (2007) Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br. J. Haematol. 139, 434-438.
24. Pennisi, A., Li, X., Ling, W., Khan, S., Zangari, M. & Yaccoby, S. (2009) The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am. J. Hematol. 84, 6-14.
25. Sato, M., Nakashima, A., Nashimoto, M., Yawaka, Y. & Tamura, M. (2009a) Bone morphogenetic protein-2 enhances Wnt/beta-catenin signaling-induced osteoprotegerin expression. Genes Cells 14, 141-153.
26. Sato, M., Nashimoto, M., Katagiri, T., Yawaka, Y. & Tamura, M. (2009b) Bone morphogenetic protein-2 down-regulates miR-206 expression by blocking its maturation process. Biochem. Biophys. Res. Commun. 383, 125-129.
27. Schwartz, A.L. & Ciechanover, A. (2009) Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu. Rev. Pharmacol. Toxicol. 49, 73-96.
28. Shah, J.J. & Orlowski, R.Z. (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23, 1964-1979.
29. Spencer, G., Utting, J., Etheridge, S., Arnett, T. & Genever, P. (2006) Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J. Cell Sci. 119, 1283-1296.
30. Tamura, M., Nemoto, E., Sato, M.M., Nakashima, A. & Shimauchi, H. (2010) Role of the Wnt signaling pathway in bone and tooth. Front. Biosci. (Elite Ed.) 2, 1405-1413.
31. Wrana, J.L. & Attisano, L. (2000) The Smad pathway. Cytokine Growth Factor Rev. 11, 5-13.
32. Xing, L., Zhang, M. & Chen, D. (2010) Smurf control in bone cells. J. Cell. Biochem. 110, 554-563.
33. Yamashita, M., Ying, S.X., Zhang, G.M., Li, C., Cheng, S.Y., Deng, C.X. & Zhang, Y.E. (2005) Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 121, 101-113.
34. Yang, X., Matsuda, K., Bialek, P., Jacquot, S., Masuoka, H.C., Schinke, T., Li, L., Brancorsini, S., Sassone-Corsi, P., Townes, T.M., Hanauer, A. & Karsenty, G. (2004) ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 117, 387-398.
35. Yu, P.B., Hong, C.C., Sachidanandan, C., Babitt, J.L., Deng, D.Y., Hoyng, S.A., Lin, H.Y., Bloch, K.D. & Peterson, R.T. (2008a) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4, 33-41.
36. Yu, S., Jiang, Y., Galson, D.L., Luo, M., Lai, Y., Lu, Y., Ouyang, H.J., Zhang, J. & Xiao, G. (2008b) General transcription factor IIA-gamma increases osteoblast-specific osteocalcin gene expression via activating transcription factor 4 and runt-related transcription factor 2. J. Biol. Chem. 283, 5542-5553.
37. Zhao, M., Qiao, M., Harris, S.E., Oyajobi, B.O., Mundy, G.R. & Chen, D. (2004) Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J. Biol. Chem. 279, 12854-12859.
38. Zhao, M., Qiao, M., Oyajobi, B.O., Mundy, G.R. & Chen, D. (2003) E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J. Biol. Chem. 278, 27939-27944.
39. Zhu, H., Kavsak, P., Abdollah, S., Wrana, J.L. & Thomsen, G.H. (1999) A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400, 687-693.